Omapatrilat. Antihypertensive, treatment of heart failure, ACE inhibitor, neutral endopeptidase inhibitor

Drugs of the Future

Volumn 24, Issue 3, 1999, Pages 269-277

  Graul, A ^a   Leeson, P ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ANTIHYPERTENSIVE AGENT; BMS 182657; CGS 26582; DAGLUTRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; ER 32935; FASIDOTRIL; OMAPATRILAT; SA 6817; SAMPRATRILAT; SCH 54470; UNCLASSIFIED DRUG; Z 13752A;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; REVIEW;

EID: 0032938106     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.03.489142     Document Type: Review

References (36)

1. Robl, J.A., Sun, C.-Q., Stevenson, J. et al. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipep-tide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997, 40: 1570-7.
2. Robl, J.A., Kronenthal, D.R., Goderey, J.D. Jr. (Bristol-Myers Squibb Co.). Bicyclic carboxylic acids and their derivs. as NEP and ACE inhibitors. EP 629627, JP 95048259, US 5508272.
3. Spotlight on double and triple enzyme inhibitors for treating cardiovascular disease. Prous Science Daily Essentials Feb 24, 1999.
4. Trippodo, N.C., Robl, J.A., Asaad, M.M., Schaeffer, T.R., Cheung, H.S. Broad spectrum antihypertensive effects of dual metalloprotease inhibition. Am J Hypertens 1997, 10(4, Part 2): 99A.
5. Trippodo, N.C., Robl, J.A., Asaad, M.M., Fox, M., Panchal, B.C., Schaeffer, T.R. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998, 11: 363-72.
6. Trippodo, N.C., Fox, M., Monticello, T.M., Panchal, B.C., Asaad, M.M. Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition. Circulation 1998, 98(17, Suppl.): Abst 4095.
7. 14C]BMS-186716 in dogs. 7th North Amer ISSX Meet (Oct 20-24, San Diego) 1996, Abst 342.
8. Jemal, M., Hawthrone, D.J. Quantitative determination of BMS-186716, a thiol compound, in rat plasma by high-performance liquid chromatography positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases. J Chromatogr B 1997, 698: 123-32.
9. Jemal, M., Hawthorne, D.J. Quantitative determination of BMS-186716, a thiol compound, in dog plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct. J Chromatogr B 1997, 693: 109-16.
10. Jemal, M., Hawthorne, D. High performance liquid chromatography/ionspray mass spectrometry of N-ethylmaleimide and acrylic acid ester derivatives for bioanalysis of thiol compounds. Rapid Commun Mass Spectrom 1994, 8: 854-7.
11. Massien, C., Azizi, M., Guyene, T.T., Ménard, J. Dual neutral endopeptidase (NEP)/angiotensin converting enzyme (ACE) inhibition is biologically different from ACE inhibition, at the same level of ACE inhibition. J Hypertens 1998, 16(Suppl. 2): Abst P31.024.
12. Azizi, M., Massien, C., Vesterqvist, O., Gielsdorf, W., Liao, W.-C., Mangold, B., Menard, J. Neutral endopeptidase (NEP)/angiotensin converting enzyme (ACE) inhibition with omapatrilat (OMA): What is beyond ACE inhibition? Circulation 1998, 98(17, Suppl.): Abst 4150.
13. Vesterqvist, O., Liao, W., Manning, J.A., Uderman, H., Delaney, C., Beierle, F., Swanson, B.N. Effects of BMS-186716, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) activity in healthy men. Clin Pharmacol Ther 1997, 61(2): Abst PIV-46.
14. Liao, W.-C., Delaney, C.L., Beierle, F.A., Ferreira, I.M., Davis, K.D., Meier, A., Vesterqvist, O., Ford, N.F., Uderman, H.D. Omapatrilat, a novel vasopeptidase inhibitor, reduces blood pressure in normotensive subjects. J Am Coll Cardiol 1999, 33(2, Suppl. A): 309A.
15. Klapholz, M., Thomas, I., Eng, C., Iteld, B.J., Ponce, G.A., Niederman, A.L., Bilsker, M., Heywood, J.T. Omapatrilat, a novel cardiovascular agent, improves hemodynamics in patients with heart failure. Circulation 1998, 98(17, Suppl.): Abst 533.
16. McClean, D.R., Melton, I.C., Crozier, I.G., Garlick, A.H., Richards, A.M., Nicholls, M.G., Ikram, H. The effects of omapatrilat, a combined inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on arterial function in chronic heart failure. Eur Heart J 1998, 19(Suppl.): Abst 1993.
17. McClean, D., Ikram, H., Melton, I., Crozier, I., Garlick, A., Richards, M., Nicholls, G., Hume, M. Cardiac, renal and endocrine effects of three month treatment of chronic heart failure with the vasopeptidase inhibitor, omapatrilat. J Am Coll Cardiol 1999, 33(2, Suppl. A): 185A.
18. Ikram, H., McClean, D.R., Mehta, S. et al. Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure. J Am Coll Cardiol 1999, 33(2, Suppl. A): 185A.
19. In development: New medicines for heart disease and stroke. America's Pharmaceutical Companies Feb 12,1999.
20. Trippodo, N.C. et al. The mixed neutral endopeptidase/ angiotensin converting enzyme inhibitor BMS-182657 produces beneficial hemodynamic effects in hamsters with heart failure. Hypertension 1994, 23: 407.
21. Robl, J.A. et al. Dual metalloprotease inhibitors. I. Constrained peptidomimetics of mercaptoacyl dipeptides. Bioorg Med Chem Lett 1994, 4: 1789.
22. Trippodo, N.C., Robl, J.A., Asaad, M.M., Bird, J.E., Panchal, B.C., Schaeffer, T.R., Fox, M., Giancarli, M.R., Cheung, H.S. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995, 275: 745-52.
23. Seymour, A.A., Abboa-Offei, B.E., Smith, P.L., Mathers, P.D., Asaad, M.M., Rogers, W.L. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995, 22: 63-9.
24. Matsuoka, T. et al. Characterization of ER-32935, a novel dual inhibitor of neutral endopeptidase and angiotensin I-converting enzyme. Jpn J Pharmacol 1996, 71(Suppl. 1): Abst P-351.
25. Gros, C., Noel, N., Souque, A., Schwartz, J.C., Danvy, D., Plaquevent, J.C., Duhamel, L., Duhamel, P., Lecomte, J.M., Bralet, J. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991, 88: 4210-4.
26. Flynn, G.A., Beight, D.W., Mehdi, S., Koehl, J.R., Giroux, E.L., French, J.F., Hake, P. W., Dage, R.C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J Med Chem 1993, 36: 2420-3.
27. Morazzoni, G., Allievi, L., Branca, E., Da Ros, B., Ferlenga, P., Legnani, G., Marchini, F., Pocchiari, F., Semeraro, C. In vitro and ex vivo characterization of Z13752A, a new dual-acting ACE/NEP inhibitor. Eur J Pharm Sci 1998, 6(Suppl. 6): Abst 139.
28. Meil, J., Wurl, M., Thormähler, D., Rose, H. Pharmacology of the active metabolite of SLV-306 - A mixed inhibitor of NEP and ECE. Naunyn-Schmied Arch Pharmacol 1998, 358(1, Suppl. 2): Abst P 52.22.
29. Ksander, G.M., Savage, P., Trapani, A.J., Balwierczak, J.L., Jeng, A.Y. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1998, 31(Suppl. 1): S71-3.
30. Ksander, G.M., de Jesus, R., Yuan, A., Ghai, R.D., McMartin, C., Bohacek, R. Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. J Med Chem 1997, 40: 506-14.
31. Fujita, Y. et al. The properties of enzyme inhibition by a novel dual inhibitor, SA6817, of neutral endopeptidase and angiotensin-converting enzyme. Jpn J Pharmacol 1997, 73(Suppl. 1): Abst P-28.
32. Vemulapalli, S. et al. Renal effects of SCH 54470: A triple inhibitor of ECE, ACE, and NEP. Cardiovasc Drug Rev 1997,15: 260.
33. Stamford, A.W. et al. Synthesis and activity of novel phosphinic acid inhibitors of endothelin converting enzyme. 212th ACS Natl Meet (Aug 25-29, Orlando) 1996, Abst MEDI 018.
34. Liao, W., Delaney, C., Smith, R., Lubin, S., McNulty, S., Davis, K., Meier, A., Uderman, H. Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), in healthy male subjects. Clin Pharmacol Ther 1997, 61(2): Abst PIV-45.
35. Robl, J.A. Dual metalloprotease inhibitor: Discovery and pharmacology of omapatrilat. FASEB J 1998, 12(8): Abst D15.
36. Thomas, C.V., Holzgrefe, H.H., Mukherjee, R. Hird, R.B., Walker, J.D., Hebbar, L., Powell, J.R., Spinale, F.G. Dual metalloprotease inhibition during the development of left ventricular failure: Effects on left ventricular myocyte β-adrenergic response. Circulation 1997, 96(8, Suppl.): Abst 2917.